This inventor holds 2 USPTO granted patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Masahiro Nogami: Innovator in Antisense Oligonucleotide Technology
Introduction
Masahiro Nogami is a prominent inventor based in Fujisawa, Japan. He is known for his significant contributions to the field of molecular biology, particularly in the development of antisense oligonucleotides. His work focuses on innovative methods for splicing modulation, which has implications for treating various diseases.
Latest Patents
Masahiro Nogami holds a patent for "Compositions and methods for splicing modulation of UNC13A." This patent describes antisense oligonucleotides designed to inhibit the inclusion of a cryptic exon into the mature mRNA of UNC13A. The patent also outlines pharmaceutical compositions that include these oligonucleotides and methods for treating UNC13A-associated diseases or conditions related to TDP-43 dysfunction.
Career Highlights
Nogami is affiliated with Takeda Pharmaceutical Company Limited, where he applies his expertise in molecular biology to advance therapeutic solutions. His innovative approach has positioned him as a key figure in the development of new treatments that leverage the power of antisense technology.
Collaborations
He collaborates with Akihiro Yokota, working together to enhance the understanding and application of their research in the pharmaceutical industry.
Conclusion
Masahiro Nogami's contributions to the field of antisense oligonucleotide technology exemplify the impact of innovative research on medical science. His work continues to pave the way for new therapeutic strategies in treating complex diseases.